Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04389450 · ClinicalTrials.gov registry record · Phase 2
Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19
A Phase 2 study, sponsored by Pluristem.
- Terminated
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT04389450 is a Phase 2 study that was terminated before completion, run by Pluristem. The registered enrollment target is 66 participants.
The verdict
NCT04389450, a Phase 2 study, was terminated before completion, sponsored by Pluristem.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
This clinical trial will examine if a new treatment of Mesenchymal-like Adherent stromal Cells (called PLX-PAD) can help patients intubated and mechanically ventilated due to COVID-19 to recover more quickly with less complications.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL PLX-PAD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2023-06-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04389450
The ClinicalTrials.gov registry entry for NCT04389450 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pluristem, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04389450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04389450 about?
NCT04389450 is a clinical study titled "Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19". This clinical trial will examine if a new treatment of Mesenchymal-like Adherent stromal Cells (called PLX-PAD) can help patients intubated and mechanically ventilated due to COVID-19 to recover more quickly with less complications.
What is the current status of trial NCT04389450?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2020-10-01. Estimated completion is 2023-06-07.
What interventions are being tested in trial NCT04389450?
The interventions under investigation include: Placebo (BIOLOGICAL), PLX-PAD (BIOLOGICAL).
Who is sponsoring clinical trial NCT04389450?
This trial is sponsored by Pluristem, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.